1. Home
  2. RDHL vs CNSP Comparison

RDHL vs CNSP Comparison

Compare RDHL & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • CNSP
  • Stock Information
  • Founded
  • RDHL 2009
  • CNSP 2017
  • Country
  • RDHL Israel
  • CNSP United States
  • Employees
  • RDHL N/A
  • CNSP N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • CNSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDHL Health Care
  • CNSP Health Care
  • Exchange
  • RDHL Nasdaq
  • CNSP Nasdaq
  • Market Cap
  • RDHL 6.8M
  • CNSP 6.5M
  • IPO Year
  • RDHL N/A
  • CNSP 2019
  • Fundamental
  • Price
  • RDHL $5.23
  • CNSP $0.14
  • Analyst Decision
  • RDHL
  • CNSP Strong Buy
  • Analyst Count
  • RDHL 0
  • CNSP 1
  • Target Price
  • RDHL N/A
  • CNSP $0.50
  • AVG Volume (30 Days)
  • RDHL 10.4K
  • CNSP 38.3M
  • Earning Date
  • RDHL 04-07-2025
  • CNSP 03-31-2025
  • Dividend Yield
  • RDHL N/A
  • CNSP N/A
  • EPS Growth
  • RDHL N/A
  • CNSP N/A
  • EPS
  • RDHL N/A
  • CNSP N/A
  • Revenue
  • RDHL $3,707,000.00
  • CNSP N/A
  • Revenue This Year
  • RDHL $224.90
  • CNSP N/A
  • Revenue Next Year
  • RDHL $82.69
  • CNSP N/A
  • P/E Ratio
  • RDHL N/A
  • CNSP N/A
  • Revenue Growth
  • RDHL N/A
  • CNSP N/A
  • 52 Week Low
  • RDHL $5.20
  • CNSP $0.08
  • 52 Week High
  • RDHL $20.28
  • CNSP $23.90
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 31.92
  • CNSP 70.62
  • Support Level
  • RDHL $5.52
  • CNSP $0.09
  • Resistance Level
  • RDHL $5.71
  • CNSP $0.12
  • Average True Range (ATR)
  • RDHL 0.27
  • CNSP 0.02
  • MACD
  • RDHL -0.04
  • CNSP 0.00
  • Stochastic Oscillator
  • RDHL 2.38
  • CNSP 52.83

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Share on Social Networks: